Nasdaq Cyad News Today

Celyad Oncology SA (NASDAQ:CYAD – Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.69 and traded as high as $0.81. Celyad Oncology shares last traded at $0.75, with a volume of 8,985 shares. Celyad Oncology Stock Down 5.1 […]

Georges Rawadi was appointed Chief Executive Officer as from April 27, 2023Celyad Oncology has received approximately EUR 9.8m in private placement...

MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company...

MONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company...

MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company...

MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage...

Celyad Oncology (NASDAQ:CYAD – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The firm presently has a $2.25 price target on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 7.66% from the company’s […]

MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext...

MONT-SAINT-GUIBERT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“Celyad” or the “Company”), a...

Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium January 18, 2021 01:00 ET | Source: Celyad Oncology SE Celyad Oncology SE Mont-Saint-Guibert, BELGIUM Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively Tumor burden decrease observed in eight of 15 refractory unresectable mCRC patients, incl...